Krishgen is the only manufacturer of ELISA for pharmacokinetic studies of BsAbs, with 40+ drug targets in a sensitive, highly specific ELISA format.
Bispecific T-Cell Engaging (BiTE) Antibodies: A Promising Cancer Therapy

Krishgen is the only manufacturer of ELISA for pharmacokinetic studies of BsAbs, with 40+ drug targets in a sensitive, highly specific ELISA format.
Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary approach in the field of cancer immunotherapy.
The Ab-Match series by MBL are innovative ELISA kits for the detection of cancer antigens. These convenient kits come with all the necessary components for successful detection.
Histone deacetylase (HDAC) plays a pivotal role in the regulation of gene expression through the modification of nucleosome structure.
mAbs (biosimilars) as tools to research novel new therapies and uncover effective off-target application.
Monoclonal antibody drugs have emerged as powerful tools in the fight against cancer, revolutionising treatment approaches.
This white paper details findings in molecular mechanisms that govern necroptosis related to RIPK & details #2283 use to analyse expression of RIPK3.
ProSci details the importance of PD-1 antibodies are important in resolving complex interactions between the immune system & pathological conditions.
MBLI offers Assay/Inhibitor screening kits designed to measure the activities of purified kinase for the rapid and sensitive evaluation of inhibitors.
Recently 5 new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 & B7-H7, were identified, all of them possibly of high interest in immunotherapy research.